WHAT INVESTORS NEED TO KNOW ABOUT HAIR GROWTH BIOTECH MANE AS STRONG TRIAL RESULTS FUEL SHORT SQUEEZE
By Nigam Arora
MANE is long from $84.88. It is trading at $146.95 as of this writing, representing a gain of approximately 73% for Arora members.
The stock is jumping following positive clinical trial results. Short covering may also be contributing to the rally.
Buyout Target
MANE is a buyout target.
To date, 232 Arora Portfolio companies have been bought out, producing large gains for members who routinely invest in buyout targets. This performance is better than that of firms that charge $50,000 per year and provide buyout advice. With The Arora Report, you get so much more.
First New FDA Approved Oral Hair Loss Treatment In Nearly 30 Years?
… Please click here or the title below to read more.
November 11, 2026